ZIOPHARM Oncology, Inc. Announces Positive ZIO-101 Clinical Data At EORTC-NCI-AACR

PRAGUE--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation by Luis Camacho, MD of the University of Texas M. D. Anderson Cancer Center of positive phase I clinical data for ZIO-101, an organic arsenic, from trials in both hematological cancers and solid tumors. Clinical activity was seen over a range of doses and ZIO-101 has now entered phase II trials. The poster was part of the 18th EORTC-NCI-AACR Symposium on “Molecular Targets, and Cancer Therapeutics” held in Prague.